Stockscreener 앱 받기
14.33
0.42%
-0.06
시간 외 거래:
14.33
전일 마감가:
$14.39
열려 있는:
$14.28
하루 거래량:
2.12M
Relative Volume:
0.78
시가총액:
$45.27B
수익:
$29.63B
순이익/손실:
$260.53M
주가수익비율:
181.85
EPS:
0.0788
순현금흐름:
$5.51B
1주 성능:
+1.06%
1개월 성능:
+1.70%
6개월 성능:
-6.89%
1년 성능:
+6.54%
1일 변동 폭
$14.20
$14.35
1주일 범위
$14.17
$14.53
52주 변동 폭
$12.80
$15.69
다케다약품공업 ADR Stock (TAK) Company Profile
명칭
Takeda Pharmaceutical Co Adr
전화
-
주소
-
TAK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-07-19 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-10-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 개시 | Cowen | Market Perform |
| 2019-08-15 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
모두보기
다케다약품공업 ADR 주식(TAK)의 최신 뉴스
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛
Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria
CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com
BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com
CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se
INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com
INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo
Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com
5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool
Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se
Japan's Takeda weighs India for global trials to speed up drug launches - MSN
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl
IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl
Waltham biotech’s latest pharma deal valued at $2B - The Business Journals
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
다케다약품공업 ADR (TAK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.73%
0.85%
자본화:
|
볼륨(24시간):